Takeda Pharmaceutical Company Profile (OTCMKTS:TKPYY)

About Takeda Pharmaceutical

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. As of March 31, 2014, the Company had 146 subsidiaries and 17 associated companies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TKPYY
  • CUSIP:
Key Metrics:
  • Previous Close: $23.11
  • 50 Day Moving Average: $21.64
  • 200 Day Moving Average: $22.14
  • 52-Week Range: $19.96 - $25.15
  • Trailing P/E Ratio: 31.21
  • P/E Growth: 0.00
  • Market Cap: $36.13B
  • Outstanding Shares: 1,563,513,000
  • Beta: 0.44
Profitability:
  • Net Margins: 7.86%
  • Return on Equity: 9.94%
  • Return on Assets: 5.00%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 1.84%
  • Quick Ratio: 1.54%
Additional Links:
Companies Related to Takeda Pharmaceutical:

Analyst Ratings

Consensus Ratings for Takeda Pharmaceutical (OTCMKTS:TKPYY) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2014$0.21ViewN/AView Earnings Details
2/5/2014Q4$0.29ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Takeda Pharmaceutical (OTCMKTS:TKPYY)
DateHeadline
us.rd.yahoo.com logoTakeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601 (OTCMKTS:TKPYY)
us.rd.yahoo.com - February 17 at 7:03 PM
finance.yahoo.com logoFive-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcer (OTCMKTS:TKPYY)
finance.yahoo.com - February 17 at 7:03 PM
News IconRegeneus Hits the Fast Track with Major Japanese Partnership (OTCMKTS:TKPYY)
jutiagroup.com - February 9 at 6:11 AM
finance.yahoo.com logoTakeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research (OTCMKTS:TKPYY)
au.finance.yahoo.com - February 9 at 6:11 AM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 2, 2017 (OTCMKTS:TKPYY)
www.capitalcube.com - February 3 at 6:16 AM
ft.com logo[$$] US biotech Ovid to develop Takeda epilepsy drug in outsourcing tie-up (OTCMKTS:TKPYY)
www.ft.com - January 19 at 4:55 AM
finance.yahoo.com logo7:34 am Takeda Pharma & Ovid Therapeutics announce innovative clinical development and commercialization collaboration for TAK-935 in rare pediatric epilepsies (OTCMKTS:TKPYY)
finance.yahoo.com - January 19 at 4:54 AM
finance.yahoo.com logoTakeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies (OTCMKTS:TKPYY)
au.finance.yahoo.com - January 19 at 4:54 AM
us.rd.yahoo.com logoMaverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies (OTCMKTS:TKPYY)
us.rd.yahoo.com - January 12 at 3:20 AM
blogs.barrons.com logoTakeda Buys Ariad For $5.2 Billion: A Good Deal? (OTCMKTS:TKPYY)
blogs.barrons.com - January 10 at 2:12 AM
nasdaq.com logoTakeda To Buy ARIAD For $24.00/shr; Accretive To FY18 Underlying Core Earnings (OTCMKTS:TKPYY)
www.nasdaq.com - January 10 at 2:12 AM
smarteranalyst.com logoStock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Enters Agreement to Be Acquired by Takeda Pharmaceutical for $5.2 Billion (OTCMKTS:TKPYY)
www.smarteranalyst.com - January 10 at 2:12 AM
bizjournals.com logoUW spinout wins $35M deal to develop therapy for celiac disease (OTCMKTS:TKPYY)
www.bizjournals.com - January 7 at 6:02 AM
us.rd.yahoo.com logoTakeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease (OTCMKTS:TKPYY)
us.rd.yahoo.com - January 6 at 6:09 AM
finance.yahoo.com logoGEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab (OTCMKTS:TKPYY)
finance.yahoo.com - December 9 at 8:07 PM
seekingalpha.com logoValeant: Avoid Post Salix/Takeda Deal Breakdown (OTCMKTS:TKPYY)
seekingalpha.com - December 2 at 11:08 AM
finance.yahoo.com logoCerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases (OTCMKTS:TKPYY)
au.finance.yahoo.com - December 2 at 11:08 AM
investopedia.com logoValeant Stock Plunges 11% on Failed Salix Sale (VRX) (OTCMKTS:TKPYY)
www.investopedia.com - December 1 at 9:47 AM
finance.yahoo.com logoValeant Said to Plan to Keep Salix After Takeda Deal Falls Apart (OTCMKTS:TKPYY)
finance.yahoo.com - November 30 at 11:36 PM
bloomberg.com logoValeant Said to Keep Salix After Takeda Deal Falls Apart (OTCMKTS:TKPYY)
www.bloomberg.com - November 30 at 11:36 PM
finance.yahoo.com logoTakeda's talks to acquire Valeant's Salix stall-sources (OTCMKTS:TKPYY)
finance.yahoo.com - November 30 at 11:36 PM
sg.finance.yahoo.com logoTakeda's talks to acquire Valeant's Salix stall - sources (OTCMKTS:TKPYY)
sg.finance.yahoo.com - November 30 at 11:36 PM
finance.yahoo.com logoTakeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany (OTCMKTS:TKPYY)
au.finance.yahoo.com - November 30 at 10:22 AM
us.rd.yahoo.com logoNINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma (OTCMKTS:TKPYY)
us.rd.yahoo.com - November 29 at 10:51 AM
us.rd.yahoo.com logo3:19 am Takeda Pharma receives conditional approval for NINLARO from the European Commission (OTCMKTS:TKPYY)
us.rd.yahoo.com - November 29 at 10:51 AM
seekingalpha.com logoValeant: Salix Rumors Send Sum-Of-The Parts Valuation Below $1 (OTCMKTS:TKPYY)
seekingalpha.com - November 24 at 7:48 PM
finance.yahoo.com logoAstraZeneca's Symbicort Positive in Pediatric Asthma Study (OTCMKTS:TKPYY)
finance.yahoo.com - November 14 at 8:09 PM
finance.yahoo.com logoTakeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus (OTCMKTS:TKPYY)
au.finance.yahoo.com - November 10 at 11:27 AM
seekingalpha.com logoValeant: $50-$70 After Salix Sale (OTCMKTS:TKPYY)
seekingalpha.com - November 3 at 7:55 PM
finance.yahoo.com logoTakeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting (OTCMKTS:TKPYY)
au.finance.yahoo.com - November 3 at 12:12 PM
benzinga.com logoValeant's Potential Salix Sale Appears To Be A Positive (OTCMKTS:TKPYY)
www.benzinga.com - November 2 at 8:20 PM
wsj.com logo[$$] Japan’s Takeda Pharmaceutical Seeks to Expand Overseas (OTCMKTS:TKPYY)
www.wsj.com - November 2 at 8:20 PM
wsj.com logo[$$] Japan's Takeda Seeks to Expand Overseas (OTCMKTS:TKPYY)
www.wsj.com - November 2 at 11:36 AM
feeds.reuters.com logoTakeda says eyeing growth options, but nothing to disclose on reported Salix deal talks (OTCMKTS:TKPYY)
feeds.reuters.com - November 2 at 2:16 AM
bloomberg.com logoValeant Said to Be in Talks for Sale of Salix to Takeda (OTCMKTS:TKPYY)
www.bloomberg.com - November 1 at 8:04 PM
finance.yahoo.com logoValeant in talks to sell Salix stomach-drug business -sources (OTCMKTS:TKPYY)
finance.yahoo.com - November 1 at 8:04 PM
capitalcube.com logoTakeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 1, 2016 (OTCMKTS:TKPYY)
www.capitalcube.com - November 1 at 12:29 PM
finance.yahoo.com logoNikkei drops as US election uncertainty sours mood; shippers jump (OTCMKTS:TKPYY)
finance.yahoo.com - October 31 at 8:23 AM
finance.yahoo.com logoPioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept (OTCMKTS:TKPYY)
finance.yahoo.com - October 31 at 8:23 AM
finance.yahoo.com logoTakeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance (OTCMKTS:TKPYY)
au.finance.yahoo.com - October 28 at 11:47 AM
finance.yahoo.com logoTakeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions (OTCMKTS:TKPYY)
finance.yahoo.com - October 28 at 11:47 AM
seekingalpha.com logoMyovant Sciences IPO Attracts Major Pharma Interest (OTCMKTS:TKPYY)
seekingalpha.com - October 26 at 11:23 AM
wsj.com logo[$$] FDA Gives Green Light to Mersana Therapeutics Cancer Clinical Trial (OTCMKTS:TKPYY)
www.wsj.com - October 24 at 7:20 PM
finance.yahoo.com logoTakeda Pharma upgraded by UBS (OTCMKTS:TKPYY)
finance.yahoo.com - October 21 at 11:18 AM
seekingalpha.com logoSucampo Pharmaceuticals Q3: Surprise Likely (OTCMKTS:TKPYY)
seekingalpha.com - October 18 at 10:05 AM
finance.yahoo.com logoTakeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma (ISHL) (OTCMKTS:TKPYY)
au.finance.yahoo.com - October 18 at 10:05 AM
nasdaq.com logoTiGenix: Cx601 For Perianal Fistula Gets Orphan Drug Designation In Switzerland (OTCMKTS:TKPYY)
www.nasdaq.com - October 17 at 7:33 PM
seekingalpha.com logoMyovant Sciences IPO Has Nothing But IP (OTCMKTS:TKPYY)
seekingalpha.com - October 17 at 7:33 PM
thestreet.com logoVedolizumab presentations include real-world and post-marketing safety data (OTCMKTS:TKPYY)
www.thestreet.com - October 17 at 7:33 PM
finance.yahoo.com logoTakeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting (OTCMKTS:TKPYY)
finance.yahoo.com - October 17 at 9:56 AM

Social

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

How do I buy Takeda Pharmaceutical stock?

Shares of Takeda Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Takeda Pharmaceutical stock cost?

One share of Takeda Pharmaceutical stock can currently be purchased for approximately $23.11.

Takeda Pharmaceutical (OTCMKTS:TKPYY) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Earnings History Chart

Earnings by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Dividend History Chart

Dividend Payments by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Last Updated on 2/20/2017 by MarketBeat.com Staff